ISAL 2019 | Triplebody development process
Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the development of the lead triplebody candidate and the manufacturing process. Prof. Fey highlights the catch 42 the team are facing in moving this agent into trials, due to the external effector cells that the therapy utilizes. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up